Remus Pharmaceuticals Ltd
REMUSRemus Pharmaceuticals Ltd
REMUS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 13.85 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.49 | 6.67 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Remus Pharmaceuticals Ltd markets and distributes pharmaceutical formulations and active pharmaceutical ingredients, specializing in various therapeutic areas including oncology and cardiovascular health.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2024 | TTM | ||
|---|---|---|---|---|
| Total Revenue | 217.90 | — | ||
Raw Materials | 164.99 | — | ||
| Power & Fuel Cost | 0.00 | |||
| Employee Cost | 7.42 | |||
| Selling & Administrative Expenses | 5.25 | |||
| Operating & Other expenses | 7.02 | |||
EBITDA | 33.22 | — | ||
| Depreciation/Amortization | 0.90 | — | ||
| PBIT | 32.32 | — | ||
| Interest & Other Items | 0.48 | — | ||
| PBT | 31.84 | — | ||
| Taxes & Other Items | 10.30 | — | ||
| Net Income | 21.54 | — | ||
| EPS | 36.56 | — | ||
| DPS | 0.00 | — | ||
| Payout ratio | 0.00 | — |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Remus Pharmaceuticals Ltd | 67.08 | 13.85 | — |
| Sun Pharmaceutical Industries Ltd | 46.13 | 6.58 | 0.73% |
| Cipla Ltd | 29.21 | 4.49 | 0.87% |
| Mankind Pharma Ltd | 62.91 | 12.57 | — |
Price Comparison
Compare REMUS with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
REMUS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 19, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Nov 19, 2024
Cash Dividend
Ex DateEx DateMay 2, 2024
Dividend/Share
₹4.00
Ex DateEx Date
May 2, 2024
Cash Dividend
Ex DateEx DateOct 27, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Oct 27, 2023
Cash Dividend
Ex DateEx DateSep 15, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Sep 15, 2023
Remus Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 9 November 2024, inter alia, have recommended the interim dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Remus Pharmaceuticals announced that the 9th Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant